Condensed Consolidated Statements of Cash Flow (Unaudited) (USD $)	9 Months Ended		128 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
Cash Flows From Operating Activities
Net loss	$ (10,647,282)	$ (15,982,768)	$ (116,432,004)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	4,579	5,737	444,378
Amortization of patents	503,340	503,340	6,621,717
Amortization of original issue discount			3,845,721
Amortization of commitment fee			310,866
Amortization of prepaid consultant expense			1,295,226
Amortization of deferred loan costs			2,261,584
Accretion of United States Treasury Bills			(373,295)
Loss on extinguishment of debt			825,867
Loss on exercise of warrants			236,146
Beneficial conversion of convertible interest			55,976
Convertible interest			389,950
Compensation through issuance of stock options	183,028	3,368,950	14,397,729
Compensation through issuance of stock			932,000
Issuance of stock for services	409,250	268,500	9,006,261
Issuance of warrants for services	1,381,329	540,316	6,065,872
Issuance of warrants for contractual obligations			985,010
Gain on sale of equipment			(55,075)
Gain on change in fair value of warrant liability	(1,435,898)	(1,059,730)	(5,580,181)
(Increase) decrease in assets
Prepaid expenses and other current assets	(16,284)	(42,415)	(16,284)
Increase (decrease) in liabilities
Accounts payable	179,513	(271,314)	276,970
Accrued expenses	1,512,859	(588,369)	1,824,111
Net cash used in operating activities	(7,925,566)	(13,257,753)	(72,681,455)
Cash Flows From Investing Activities
Proceeds from sale of fixed assets			180,075
Capital expenditures	(15,885)	(6,147)	(89,920)
Proceeds from sales of investments			37,010,481
Purchases of investments			(36,637,186)
Net cash (used in) provided by investing activities	(15,885)	(6,147)	463,450
Cash Flows From Financing Activities
Net proceeds from loans from stockholder			174,000
Proceeds from convertible debt			6,706,795
Net proceeds from sales of preferred stock and warrants			8,908,131
Net proceeds from sales of common stock and warrants	2,077,796	9,486,071	40,101,773
Proceeds from exercises of warrants and stock options		6,504,209	21,078,014
Cash paid to retire convertible debt			(2,385,959)
Cash paid for deferred loan costs			(747,612)
Premium paid on extinguishments of debt			(170,519)
Purchase and retirement of common stock			(48,000)
Net proceeds from sale non-controlling interest in Pure-ific Corporation			443,500
Net cash provided by financing activities	2,077,796	15,990,280	74,060,123
Net change in cash and cash equivalents	(5,863,655)	2,726,380	1,842,118
Cash and cash equivalents, at beginning of period	7,705,773	8,086,200
Cash and cash equivalents, at end of period	1,842,118	10,812,580	1,842,118
Supplemental Disclosure of Noncash Investing and Financing Activities:
Amount reclassified from warrant liability to equity		$ 485,467